Cue Biopharma, Inc. (CUE) - 10-K Summary
Business Context and Reporting Period
Company: Cue Biopharma, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics using its Immuno-STAT platform to modulate T cells for autoimmune and inflammatory diseases. The company has no commercial products and relies on collaboration revenue and equity financing.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $27.5 | $9.3 |
| Research & Development Expenses | $37.7 | $36.3 |
| General & Administrative Expenses | $16.2 | $14.6 |
| Net Loss | $(26.6) | $(40.7) |
| Cash and Cash Equivalents (Year End) | $27.1 | $22.5 |
| Accumulated Deficit | $(368.5) | $(341.9) |
Liquidity: As of December 31, 2025, the company held $27.1 million in cash. Management estimates this is sufficient to fund operations into the first quarter of 2027. The company has no debt outstanding as of year-end (term loan fully repaid).
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased by $18.2 million (196%) year-over-year, driven primarily by new agreements with Boehringer Ingelheim (BI) and ImmunoScape Pte. Ltd. (IMSCP).
- Net Loss Reduction: Net loss decreased by $14.1 million to $26.6 million, largely due to the significant increase in collaboration revenue offsetting operating expenses.
- Strategic Shifts:
- BI Agreement (April 2025): Licensed CUE-501 (B cell depletion) to BI for an upfront payment of $10.1 million (net of withholding) and potential milestones up to $345 million.
- IMSCP Agreement (November 2025): Licensed CUE-100 series (oncology) to IMSCP. Received $9.5 million upfront (net), $10.0 million in time-based payments, and a 40% equity stake in IMSCP. Recognized $18.9 million in revenue.
- Ono Termination: Terminated the collaboration with Ono Pharmaceutical in March 2025, regaining worldwide rights to CUE-401.
- Expense Drivers: R&D expenses increased due to acquired in-process R&D costs ($3.9 million) related to the IMSCP investment and increased manufacturing costs for CUE-401. G&A expenses rose due to professional fees associated with new deal negotiations and severance costs.
Guidance, Outlook, and Risks
Going Concern Warning: The filing explicitly states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern. The company will require substantial additional capital to fund operations beyond Q1 2027.
Outlook & Milestones:
- CUE-401: Lead autoimmune candidate. IND-enabling studies are nearing completion. The company plans to file an Investigational New Drug (IND) application in Q2 2026, with human safety data expected in H2 2026.
- Financing Needs: Future funding is expected to come from equity offerings, collaborations, or strategic alliances. Recent equity offerings in 2025 raised approximately $28.3 million net.
Key Risks:
- Capital Shortfall: Inability to raise additional capital could force the company to delay, reduce, or discontinue development programs or liquidate.
- Delisting Risk: The company received a deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price. It is in a compliance period until May 11, 2026, and has proposed a reverse stock split (1-for-30 to 1-for-50) subject to shareholder approval.
- Development Risk: All drug candidates are preclinical or early clinical. Success in preclinical studies does not guarantee clinical success.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter 2027" cash runway estimate given the high burn rate and potential for unexpected expenses.
- Reverse Stock Split: Monitor the shareholder vote on the proposed reverse stock split (April 13, 2026) to avoid potential delisting from Nasdaq.
- IMSCP Equity Valuation: Review the valuation methodology for the 40% equity stake in ImmunoScape, which was expensed as R&D ($3.9 million) due to basis differences, and assess the potential upside of this investment.
- IND Filing Timeline: Confirm the Q2 2026 IND filing date for CUE-401, as delays could impact the company's ability to secure future funding.
- Collaboration Milestones: Track the achievement of preclinical milestones with Boehringer Ingelheim and ImmunoScape to trigger future payments.